The 21st Century Cures Act
Implications for Research and Drug Development


Brief Video Highlight

THE 21st CENTURY CURES ACT: Implications for Research and Drug Development
Presented jointly with STAT

Monday, February 27, 2017

The passage of the 21st Century Cures Act has drawn both applause and criticism. A sweeping bipartisan effort with multiple components, the law dramatically boosts funding for medical research, particularly in areas such as cancer and brain disease. The law also relaxes regulatory processes for pharmaceuticals and medical devices. In doing so, the law’s supporters point to the potential for faster treatments benefiting from a streamlined approval process. Critics raise concerns that safety and efficacy might be compromised, with potentially devastating consequences. And the law also has been questioned for failing to explicitly address high drug prices, a growing public issue. These debates are unfolding as the Trump administration is expected to imminently announce its choice for a new FDA commissioner, who will head an agency directly impacted by the Cures act. (Update since this event: President Trump has nominated Scott Gottlieb for FDA commissioner). In this Forum, experts will explore the implications of the law for biomedicine, regulation, pharmaceuticals and patient advocacy.

Part of: .

Presented jointly with STAT

Image Credit: iStock: 4X-image